Jovandaric, Miljana Z. (56748058300)Miljana Z. (56748058300)JovandaricDespotovic, Dina J. (57188972250)Dina J. (57188972250)DespotovicJesic, Milos M. (57211511149)Milos M. (57211511149)JesicJesic, Maja D. (24073164000)Maja D. (24073164000)Jesic2025-06-122025-06-122016https://doi.org/10.3109/15513815.2016.1164773https://www.scopus.com/inward/record.uri?eid=2-s2.0-84964514046&doi=10.3109%2f15513815.2016.1164773&partnerID=40&md5=b302edaddd9ef5b7fabe4a4e75512fd2https://remedy.med.bg.ac.rs/handle/123456789/7669Introduction: Acquired autoimmune myasthenia gravis (MG) is an autoimmune process in which antibodies (AB) directed against the acetylcholine nicotinic receptor (AChR) cause weakness and fatigue of striated muscles. Objectives: The objective of this study was to determine the range of clinical manifestations in newborns with transient neonatal myasthenia (TNM). Methods: 62 newborns with mothers who had autoimmune MG were followed by: anthropometric parameters, gestational age, gender, type of delivery completion, Apgar score (AS) in the first and fifth minute, and the emergence of TNM symptoms. Results: For fourteen consecutive years, from a total of 98,000 infants, 62 (0.06%) were born to mothers with autoimmune MG. Four of them (6.4%) had symptoms of TNM. Conclusion: Newborns of mothers with MG manifest clinical features of TNM relative to stage of mother's illness. These newborns need monitoring until the seventh day of life. © 2016 Taylor & Francis Group, LLC.autoimmune myasthenia gravisnewbornpregnancy